# Study Evaluating Single Doses of GAP-134

> **NCT00820521** · PHASE1 · WITHDRAWN · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer**

## Conditions studied

- Healthy Subjects

## Interventions

- **DRUG:** active
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00820521
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-02
- **Primary completion:** 2009-04
- **Final completion:** 2009-04
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2018-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00820521

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00820521, "Study Evaluating Single Doses of GAP-134". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00820521. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*